Business Description
NeuroOne Medical Technologies Corp
NAICS : 339113
SIC : 5047
Description
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram(cEEG) and stereoelectrocencephalography(sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 43.87 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.01 | |||||
| Beneish M-Score | -3.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.58 | |||||
| 9-Day RSI | 31.22 | |||||
| 14-Day RSI | 39.61 | |||||
| 6-1 Month Momentum % | 68.38 | |||||
| 12-1 Month Momentum % | -50.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.41 | |||||
| Quick Ratio | 12.85 | |||||
| Cash Ratio | 12.49 | |||||
| Days Inventory | 345.36 | |||||
| Days Sales Outstanding | 90.65 | |||||
| Days Payable | 752.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -55.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -47.68 | |||||
| Operating Margin % | -7466.23 | |||||
| Net Margin % | -7462.25 | |||||
| ROE % | -102.26 | |||||
| ROA % | -92.99 | |||||
| ROIC % | -1465.3 | |||||
| ROC (Joel Greenblatt) % | -2284.67 | |||||
| ROCE % | -100.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 150.57 | |||||
| PB Ratio | 2.28 | |||||
| Price-to-Tangible-Book | 2.6 | |||||
| EV-to-EBIT | -1.31 | |||||
| EV-to-EBITDA | -1.32 | |||||
| EV-to-Revenue | 97.04 | |||||
| EV-to-Forward-Revenue | 5.05 | |||||
| EV-to-FCF | -1.45 | |||||
| Price-to-Net-Current-Asset-Value | 2.69 | |||||
| Price-to-Net-Cash | 2.92 | |||||
| Earnings Yield (Greenblatt) % | -77.05 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NMTC
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.151 | ||
| EPS (TTM) ($) | -0.76 | ||
| Beta | 0.62 | ||
| Volatility % | 157.57 | ||
| 14-Day RSI | 39.61 | ||
| 14-Day ATR ($) | 0.197642 | ||
| 20-Day SMA ($) | 1.88875 | ||
| 12-1 Month Momentum % | -50.13 | ||
| 52-Week Range ($) | 0.5101 - 4.2499 | ||
| Shares Outstanding (Mil) | 16.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeuroOne Medical Technologies Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuroOne Medical Technologies Corp Analysis
Share your researchHeadlines
See More
No news.